CoverageForm 410-K10-Q8-K13D13G13F

BCPC · Balchem Corp - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · BCPC

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue$270.71M-$267.56M$255.47M$250.52M-$239.94M$234.08M$239.66M-
Cost of Revenue$169.63M-$172.10M$162.35M$162.35M-$154.58M$151.09M$158.15M-
Gross Profit$101.08M-$95.45M$93.11M$88.17M-$85.36M$82.99M$81.51M-
R&D$5.88M-$4.50M$4.30M$4.66M-$4.33M$3.85M$4.10M-
SG&A$18.48M-$17.29M$18.07M$15.56M-$17.48M$15.33M$17.51M-
Total Operating Expenses$45.46M-$40.87M$41.67M$37.15M-$37.37M$37.20M$39.84M-
D&A$12.49M-$11.55M$11.40M$11.01M-$10.90M$12.51M$13.67M-
Operating Income$55.63M-$54.58M$51.44M$51.02M-$47.99M$45.80M$41.68M-
Interest Expense----------
Income Tax$12.24M-$11.76M$10.73M$10.89M-$10.06M$9.16M$7.86M-
Net Income$40.28M-$40.29M$38.28M$37.05M-$33.84M$32.07M$28.99M-
EPS - Basic$1.26-$1.25$1.18$1.14-$1.05$0.99$0.90-
EPS - Diluted$1.25-$1.24$1.17$1.13-$1.03$0.98$0.89-

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$72.87M$74.57M$65.09M$65.43M$49.90M$49.52M$73.69M$63.74M$60.35M$64.45M
Accounts Receivable$154.23M$143.60M$131.54M$135.98M$130.45M$119.66M$120.54M$123.40M$139.88M$125.28M
Inventory$146.74M$131.45M$132.44M$148.15M$144.93M$130.80M$118.51M$117.10M$110.38M$109.52M
Accounts Payable$70.73M$60.42M$46.98M$67.86M$65.97M$54.74M$46.46M$54.50M$59.80M$55.50M
Current Assets$388.94M$365.61M$343.71M$364.86M$340.24M$313.77M$325.99M$320.16M$324.86M$314.24M
Total Assets$1.69B$1.69B$1.66B$1.68B$1.62B$1.58B$1.60B$1.57B$1.59B$1.60B
Current Liabilities$152.54M$176.38M$126.37M$138.14M$139.56M$157.69M$109.44M$113.32M$124.42M$148.49M
Long-term Debt----------
Total Liabilities$408.63M$428.84M$363.17M$410.33M$408.85M$425.46M$419.72M$462.60M$509.91M$543.23M
Stockholders' Equity$1.29B$1.26B$1.30B$1.27B$1.21B$1.15B$1.18B$1.11B$1.08B$1.05B
Retained Earnings$1.16B$1.12B$1.11B$1.07B$1.03B$997.49M$992.38M$958.54M$926.47M$897.49M

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow$40.06M---$36.46M---$33.39M-
Investing Cash Flow($6.29M)---($5.91M)---($6.74M)-
Financing Cash Flow($34.78M)---($31.97M)---($30.02M)-
CapEx----------
Free Cash Flow----------

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin37.3%-35.7%36.4%35.2%-35.6%35.5%34.0%-
Operating margin20.5%-20.4%20.1%20.4%-20.0%19.6%17.4%-
EBITDA margin25.2%-24.7%24.6%24.8%-24.5%24.9%23.1%-
Net margin14.9%-15.1%15.0%14.8%-14.1%13.7%12.1%-
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue2.2%-1.7%1.7%1.9%-1.8%1.6%1.7%-
SG&A / Revenue6.8%-6.5%7.1%6.2%-7.3%6.5%7.3%-
Effective tax rate23.3%-22.6%21.9%22.7%-22.9%22.2%21.3%-
Return on assets2.4%-2.4%2.3%2.3%-2.1%2.0%1.8%-
Return on equity3.1%-3.1%3.0%3.1%-2.9%2.9%2.7%-
Return on invested capital----------
Liquidity
Current ratio2.552.072.722.642.441.992.982.832.612.12
Quick ratio1.591.331.671.571.401.161.901.791.721.38
Cash ratio0.480.420.520.470.360.310.670.560.490.43
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier1.321.341.281.321.341.371.361.421.471.52
Liabilities / Assets0.240.250.220.240.250.270.260.290.320.34
Efficiency
Asset turnover0.16-0.160.150.15-0.150.150.15-
Inventory turnover1.16-1.301.101.12-1.301.291.43-
Days sales outstanding208d-179d194d190d-183d192d213d-
Days inventory outstanding316d-281d333d326d-280d283d255d-
Days payable outstanding152d-100d153d148d-110d132d138d-
Cash conversion cycle372d-361d375d368d-353d344d330d-
Valuation
P / E135.6x-121.0x136.1x146.9x-170.9x157.1x174.1x-
P / B4.3x-3.8x4.1x4.5x-4.9x4.5x4.7x-
P / S20.2x-18.3x20.4x21.7x-24.0x21.5x21.1x-
EV / EBITDA79.3x-73.0x81.7x87.0x-96.7x85.1x90.3x-
Growth
Revenue growth (YoY)8.1%-11.5%9.1%4.5%-4.3%1.2%3.1%-
Revenue CAGR (3y)5.2%-3.1%2.6%3.1%-6.6%5.0%8.9%-
Revenue CAGR (5y)7.8%-8.8%8.1%7.5%-8.6%7.7%8.8%-
Gross profit growth (YoY)14.6%-11.8%12.2%8.2%-11.5%7.3%11.4%-
Operating income growth (YoY)9.0%-13.7%12.3%22.4%-10.0%6.9%21.1%-
Net income growth (YoY)8.7%-19.1%19.4%27.8%-16.4%6.5%27.6%-
EPS growth (YoY)10.6%-20.4%19.4%27.0%-14.4%5.4%27.1%-
EPS CAGR (3y)21.3%-16.7%8.3%8.3%-10.2%11.9%7.3%-
EPS CAGR (5y)11.7%-13.4%12.5%13.1%-10.0%9.9%8.9%-
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)6.3%9.3%10.2%14.0%12.0%9.1%14.8%10.5%10.8%12.3%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-12-31.

Business segments

$1.03B total
Human Nutrition And Health$659.39M · 63.9%
Animal Nutrition And Health$230.85M · 22.4%
Specialty Products$140.98M · 13.7%

Product / service

$1.04B total
Product Sales$1.04B · 99.8%
Royalty$1.89M · 0.2%

Geographic

$1.04B total
US$759.45M · 73.2%
Non Us$277.71M · 26.8%

Peer comparison

Same SIC group: Chemicals & Allied Products

CompanyRevenue (last FY)Net marginROE
FMC$3.47B-64.6%-108.1%
CC$5.81B-6.6%-154.4%
OLN$6.78B-1.5%-5.5%
NGVT$1.17B-14.3%-562.6%
IOSP$1.78B6.6%8.8%

Comparing BALCHEM CORP against the 5 most active filers in the same SIC group.

Dividends

$0.96/share trailing 12 months · +10.3% YoY

Ex-datePer share
Dec 23, 2025$0.9600
Dec 26, 2024$0.8700
Dec 26, 2023$0.7900
Dec 23, 2022$0.7100
Dec 27, 2021$0.6400
Dec 24, 2020$0.5800
Dec 27, 2019$0.5200
Dec 24, 2018$0.4700
Dec 26, 2017$0.4200
Dec 22, 2016$0.3800
Dec 23, 2015$0.3400
Dec 24, 2014$0.3000
Dec 19, 2013$0.2600
Dec 12, 2012$0.2200
Dec 12, 2011$0.1800
Dec 17, 2010$0.1500
Dec 28, 2009$0.0733
Dec 18, 2008$0.0733
Dec 18, 2007$0.0733
Dec 27, 2006$0.0400
Dec 28, 2005$0.0267
Dec 28, 2004$0.0178
Dec 24, 2003$0.0158
Dec 23, 2002$0.0158